Enliven Therapeutics, Inc. (ELVN) Financials

ELVN Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 464.9 million 11.5 million
Dec. 31, 2025 476.2 million 16.7 million
Sept. 30, 2025 490.9 million 14.8 million
June 30, 2025 503.9 million 15.4 million

ELVN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -19.3 million 7.4 million
Dec. 31, 2025 -15.8 million 12.3 million
Sept. 30, 2025 -13.3 million 7.2 million
June 30, 2025 -17.2 million 7.7 million

ELVN Net Income

No data available :(

ELVN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 452.4 million - 302000
Dec. 31, 2025 462.6 million - 399000
Sept. 30, 2025 477.6 million - 387000
June 30, 2025 490.5 million - 580000

ELVN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 62.8 million
Dec. 31, 2025 56.7 million
Sept. 30, 2025 62.1 million
June 30, 2025 52.1 million

ELVN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 20.7 million 7.1 million -
Dec. 31, 2025 - 21.2 million 13.0 million -
Sept. 30, 2025 1000 18.2 million 6.9 million -
June 30, 2025 139000 21.5 million 7.1 million -

ELVN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 14000
Dec. 31, 2025 - 46000
Sept. 30, 2025 - -
June 30, 2025 - 81000

ELVN

Price: $42.36

52 week price:
14.79
48.53

Earnings Per Share: -1.64 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 2.1 billion

Links: